1Xu Y,Wang LM,He J,et al. Prevalence and control of di-abetes in Chinese adults [J]. JAMA, 2013 ? 310 (9 ) : 948-958.
2Dluhy RG,Mcmahon GT. Intensive glycemic control in theACCORD and ADVANCE trials[J]. N Engl J Med,2008,358(24):2630-2633.
3Gerich JE. Role of the kidney in normal glucose homeo-stasis and in the hyperglycaemia of diabetes mellitus : ther-apeutic implications [J]. Diabet Med, 2010, 27 (2) : 136-142.
4Lee YJ,Lee YJ,Han HJ. Regulatory mechanisms of Na( + )/glucose cotransporters in renal proximal tubule cells[J]. Kidney Int Suppl,2007(16) :S27-35.
5Malatiali S,Francis I,Barac-Nieto F. Phlorizin preventsglomerular hyperfiltration but not hypertrophy in diabeticrats[J]Exp Diabetes Res*2008 : 305403.
6Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin,anovel selective inhibitor of low-affinity Sodium glucosecotransporter ( SGLT2 ),validates the critical role ofSGLT2 in renal glucose reabsorption and modulates plas-ma glucose level [J], J Pharmacol Exp Ther, 2007, 320(1):323-330.
7Fujimori Y, Katsuno K,Ojima K, et al. Sergliflozin eta-bonate,a selective SGLT2 inhibitor, improves glycemiccontrol in streptozotocin-induced diabetic rats and Zuckerfatty rats[J]. Eur J Pharmacol,2009 ,609(1/3) : 148-154.
8Hussey EK,Clark RV, Amin DM,et al. Early clinical studiesto assess the safety, tolerability, pharmacokinetics andpharmacodynamics of single doses of Sergliflozin,a novelinhibitor of renal glucose reabsorption, in healthy volun-teers and subjects with type 2 diabetes mellitus[J]. Diabe-tes,2007 ,56(S1) : 189.
9Fujimori Y,Katsuno K, Nakashima I, et al. Remogliflozinetabonate,in a novel category of selective low-affinity So-dium glucose cotransporter (SGLT2) inhibitors, exhibitsantidiabetic efficacy in rodent models[J]. J Pharmacol ExpTher,2008,327(1) :268-276.
10Sykes AP’Kemp GL,Dobbins R, et al. Randomized effi-cacy and safety trial of once-daily emogliflozin etabonatefor the treatment of type 2 diabetes [J]. Diabetes ObesMetab,2015,17(1) :98-101.
